Luxturna Gene Therapy OK’d for Rare Form of Vision Loss A historic approval, Luxturna (voretigene neparvovec-rzyl) from Spark Therapeutics is the first directly administered gene therapy that targets a disease caused by specific gene…Original Article
You may also like
Territory Sales Representative
Biopsy Sales Specialist – Miami, FL
Clinical Specialist
Medical Device Sales – Modesto, CA
Associate Territory Manager, Neurovascular –...
Aesthetic Surgical Rep Austin/San Antonio- Allergan...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.